BioSig Technologies (BSGM) Awarded U.S. Patent Claims for its NeuroClear Subsidiary

• The patent is exclusively licensed from Mayo Foundation for Medical Education and Research
• Claims address methods and materials for improving the treatment of hypertension
• Fifteen additional licensed worldwide patent applications are pending, generally covering electroporation and stimulation

BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the U.S. Patent Office had allowed a utility patent that its majority-owned subsidiary NeuroClear Technologies, Inc. has exclusively licensed from the Mayo Foundation for Medical Education and Research.

The recently allowed patent application number 16/805,017 entitled "Systems and Methods for Electroporation" was filed on February 28, 2020. The patent describes and claims methods and materials for improving the treatment of hypertension via electroporation of nerves in the renal area. Electroporation is an emerging technique that has demonstrated efficacy in treatments for several critical conditions and is currently being evaluated for the treatments of autonomic nervous disorders, including hyper- and hypotension / syncope.

The allowed patent application complements BioSig’s expanding patent portfolio, which now includes nine allowed/issued patents. Sixteen additional worldwide utility patent applications are pending covering various aspects of its PURE EP™ System for recording, measuring, calculating, and displaying of electrocardiograms during cardiac ablation procedures. The Company has two additional pending U.S. patent applications directed to artificial intelligence (AI). BioSig has 24 allowed/issued worldwide design patents covering various features of its display screens and graphical user interface for enhanced visualization of biomedical signals. Finally, in addition to the patent referenced above, BioSig has exclusive licenses to 15 additional worldwide utility patent applications from Mayo Foundation for Medical Education and Research that are pending. These 15 applications are generally directed to electroporation and stimulation.

"We are pleased to announce this newest patent allowance which creates a patent foundation for the development of our N-SENSE™ platform technology. Our first neurostimulation product aims to address a vast market of neurological conditions through a proprietary sensing design and algorithms tailored to specific applications. Electroporation is a novel technique that has significantly advanced cancer treatments and has shown promise in treating cardiovascular disease. We look forward to exploring it further with our research partners,” commented Kenneth L. Londoner, Chairman, and CEO of BioSig Technologies, Inc.

You May Also Be Interested In

• Kopin (KOPN) loses litigation with BlueRadios, ordered to pay $5.1M
• Xiao-I Corporation (AIXI) Says Virtual Try-on Technology Achieves Significant Breakthroughs
• CEL-SCI Corp (CVM) Appoints Mario Gobbo to Its Board